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Abstract
Background: Human mesenchymal stromal cells (MSC) hold a promise for future cell-based therapies due to their 
immunomodulatory properties and/or secretory activity. Nevertheless non-neoplastic tumor compartment could also 
originate from MSC. We aimed to show whether multipotent MSC derived from human adipose tissue (AT-MSC) could 
create tumor cell-protective milieu and affect tumor cell behaviour in vitro and in vivo.
Results: Here we have demonstrated tumor-promoting effect of AT-MSC on human melanoma A375 cells. AT-MSC 
coinjection mediated abrogation of tumor latency and supported subcutaneous xenotransplant growth from very low 
melanoma cell doses. Tumor incidence was also significantly increased by AT-MSC-derived soluble factors. AT-MSC 
supported proliferation, suppressed apoptosis and modulated melanoma cell responses to cytotoxic drugs in vitro. 
Expression and multiplex cytokine assays confirmed synergistic increase in VEGF that contributed to the AT-MSC-
mediated support of A375 xenotransplant growth. Production of G-CSF and other factors implicated in formation of 
supportive proinflammatory tumor cell microenvironment was also confirmed. SDF-1α/CXCR4 signalling contributed 
to tumor-promoting effect of systemic AT-MSC administration on A375 xenotransplants. However, no support was 
observed for human glioblastoma cells 8MGBA co-injected along with AT-MSC that did not sustain tumor 
xenotransplant growth in vivo. Tumor-inhibiting response could be attributed to the synergistic action of multiple 
cytokines produced by AT-MSC on glioblastoma cells.
Conclusions: Herein we provide experimental evidence for MSC-mediated protective effect on melanoma A375 cells 
under nutrient-limiting and hostile environmental conditions resulting from mutual crosstalk between neoplastic and 
non-malignant cells. This tumor-favouring effect was not observed for the glioblastoma cells 8MGBA. Collectively, our 
data further strengthen the need for unravelling mechanisms underlying MSC-mediated modulation of tumor 
behaviour for possible future MSC clinical use in the context of malignant disease.
Background
Mesenchymal stromal cells (MSC) represent a heteroge-
neous population of multi-potent cells with beneficial
properties for regenerative processes and/or immuno-
modulation [1]. Therapeutic benefit for patients suffering
from a wide range of severe pathologic conditions was
reported in clinical trials employing MSC and derivatives
thereof [2-5]. However, MSC therapy may also bring
adverse effects such as increased recurrence rate of
hematologic malignancy as recently reported [6].
Increasing evidence has shown that MSC might play a
role in the tumor pathogenesis and progression. Tumor
behaviour is affected by non-neoplastic compartment of
stroma composed from extracellular matrix, blood ves-
sels, connective tissue, MSC, immune and inflammatory
cells dynamically interlinked with tumor parenchyma [7-
10]. Its growth results from the neoplastic cells' interac-
tion with the complex stromal compartment and compo-
nents thereof can be derived from progenitors residing in
the bone-marrow [11,12].
Mutual cellular interactions of MSC and tumor cells
were investigated in several studies to unravel the MSC
effect on tumor properties. Human MSC maintained
under standard culture conditions were shown to be non-
tumorigenic  per se, however, several reports presented
their capability to modulate tumor microenvironment
thus having an impact on the tumor behaviour [13]. MSC
produce cytokines with proangiogenic action, MSC can
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give rise to endothelial-like or pericyte-like cells contrib-
uting to tumor vasculature formation and stabilization
when recruited to the site of tumor formation [12]. MSC
exhibited a capability to differentiate into carcinoma-
associated fibroblasts upon culture under the influence of
tumor-cell produced soluble factors in vitro consequently
leading to tumor growth support in vivo [14]. Unmanipu-
lated human MSC were shown to increase the metastatic
potential of breast cancer cells rather than significant
tumor growth support [15]. Several other studies aimed
on modelling of the interplay between tumor cells and
non-tumorigenic stromal cells have shown various MSC
effects on tumor cell behaviour in vitro and in vivo. MSC
strongly inhibited proliferation of malignant cells of
hematopoietic origin in vitro, nevertheless significantly
increased BV173 tumor incidence in vivo [16]. Authors
h y p o t h e s i z e d  t h a t  M S C  w e r e  c a p a b l e  t o  p r e s e rv e  s e l f -
renewal potential of leukemic cells by mimicking cancer
stem cell niche. Increased tumor incidence rather than
change in tumor growth rate was reported for renal cell
carcinoma, colon carcinoma and melanoma cells coin-
jected with MSC in syngeneic model [17]. Moreover, sys-
temically administered MSC increased tumor incidence
and allowed for the proliferation of renal carcinoma cells.
Zhu et al. have shown similar effects of MSC-favoured
tumor growth for two colon carcinoma cell lines upon
coinjection with bone marrow-derived human MSC on
xenogeneic model [18]. Glioma outgrowth was signifi-
cantly supported by intracranial or subcutaneous tumor
cell coimplantation together with human adipose tissue
derived MSC [19].
On the contrary, there were several reports to show the
anti-tumor effect of MSC. Khakoo et al. have used sys-
temic MSC injection to inhibit the growth of Kaposi's sar-
coma subcutaneous xenotransplant [20]. Prolongation of
latent tumor time and tumor size decrease was shown for
hepatoma cells coinjected with immortalized human fetal
MSC [21]. Furthermore, MSC coimplantation with breast
cancer cells resulted in inhibited tumor growth and
reduced metastasis in vivo. [22]. Intratumoral injection of
rat MSC prolonged survival in 9L glioma-bearing rats as
a consequence of retarded tumor growth [23]. Several
studies employing MSC as tumor-targeting delivery vehi-
cles including our observations have reported no signifi-
cant influence on tumor growth in vivo [24-26].
In our present study we aimed to examine the influence
of human adipose tissue derived mesenchymal stromal
cells (AT-MSC) on tumor development. AT-MSC could
protect human melanoma cells from nutrient limitations
and/or cytotoxic effects by apoptosis inhibition in vitro.
Tumor-favouring effects on melanoma A375 xenografts
were highly AT-MSC dose dependent in vivo and tumor
incidence increase in immunocompromised host recapit-
ulated data from syngeneic model reported previously
[17]. However, AT-MSC did not increase proliferation of
glioblastoma 8MGBA cells and could suppress glioblas-
toma 8MGBA xenograft growth in vivo. We hypothesized
that the diversity in and responsiveness to paracrine fac-
tors produced by AT-MSC and given tumor cell lines
resulted in differential tumor microenvironment compo-
sition affecting outcome of mutual tumor cell/AT-MSC
interplay.
Results
AT-MSC support melanoma growth and increase tumor 
incidence in vivo
In order to determine, whether AT-MSC exhibit tumor
s u p p o r t i v e  o r  i n h i b i t o r y  e f f e c t  o n  m e l a n o m a  c e l l s ,  w e
first admixed AT-MSC to melanoma cell doses with 100%
tumor penetrance. AT-MSC coimplanted with M4Beu
melanoma cells significantly decreased time to 100%-
tumor onset in comparison to M4Beu alone. Average
tumor burden was higher in M4Beu/AT-MSC (ratio 5:1)
group in comparison to the control group (Fig. 1A and
1B). Similarly, A375/AT-MSC (5:1 ratio) injected group of
animals also exhibited shortened time to tumor onset
from 10 days in A375 alone-group to 3 days concomi-
tantly exhibiting tendency to higher average tumor vol-
ume in AT-MSC coinjected groups (Fig. 1C and 1D).
Next, we aimed to determine whether AT-MSC could
affect tumor incidence for limited amounts of tumor
cells, which leave almost all animals long term tumor free
(1 × 105  A375). AT-MSC coinjection significantly
increased tumor incidence and tumor growth in groups
coinjected with 10:1 or 1:1 AT-MSC to A375 cell ratio
(Fig. 2A). Moreover, soluble AT-MSC produced factors
were sufficient to increase tumor incidence, if AT-MSC
conditioned cell-free medium was used for the A375 cell
resuspension, which indicated a role of paracrine factors
in tumor-promoting action. Tumor volume as a measure
of tumor burden within the treatment groups was pro-
portional to the amount of coinjected AT-MSC and sig-
nificantly higher in comparison to tumor burden in
control group due to earlier latency abrogation (Fig. 2B-
C ) .  T h u s  w e  c o n c l u d e  t h a t  A T - M S C  c o u l d  a b r o g a t e
tumor latency for as low as 100,000 melanoma A375 cells,
which would not produce tumors if injected alone in
immunocompromised host.
AT-MSC can support proliferation, protect melanoma A375 
cells from nutrient deprivation or cytotoxic cellular stress in 
vitro
Coculture experiments in vitro were designed to charac-
terize the interaction between tumor cells A375 and AT-
MSC to unravel mechanism responsible for the protum-
origenic effect. In order to determine the effect on tumor
cell proliferation, A375 cells stably expressing EGFP
(EGFP-A375) were mixed with increasing amounts ofKucerova et al. Molecular Cancer 2010, 9:129
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AT-MSC or conditioned medium produced from corre-
sponding amount of AT-MSC cells. Output fluorescence
was proportional to the number of EGFP-A375 cells and
the amount of admixed AT-MSC cells did not interfere
with output fluorescence. Soluble factors supported
EGFP-A375 proliferation even in serum-limiting culture
conditions although to much lesser extent in comparison
to directly cocultured cells (Fig. 3A). AT-MSC also pro-
tected tumor cells from serum-deprivation induced
apoptosis (A375/AT-MSC ratio 10:1, Fig. 3B). Direct
cocultures of melanoma cells with AT-MSC (ratio 10:1)
did not exhibit change in effector caspase activation
induced by cytotoxic drugs in standard serum concentra-
tions (not shown). However, doxorubicin and cisplatin
treatment under serum deprivation conditions resulted
in AT-MSC-mediated significant decrease in effector cas-
pase-3/7 activation consequently leading to decrease in
proportion of apoptotic and dead cells (Fig. 3C and 3D).
Our data suggest that AT-MSC may assist tumor cells to
sustain cellular stress such as nutrient deprivation and/or
cytotoxicity. Indeed, in the presence of AT-MSC there
was a significant increase of A375 colony-forming ability
even in the absence of cell-cell contact in vitro (Fig. 4A).
No such effect was observed when AT-MSC were added
to the cultures three days later, so AT-MSC seemed to ini-
tiate colony growth at early stage. Indirect cocultures of
melanoma and AT-MSC cells enabled us to analyze the
expression of growth factors and receptors that was pre-
viously implicated to play a role in AT-MSC/tumor cell
interactions. Quantitative analysis unravelled increased
CCL5 production from AT-MSC in response to mela-
noma cells (Fig. 4B). Sustained expression of several
potential prosurvival and proangiogenic factors and their
cognate receptors in AT-MSC and A375 was demon-
strated even upon 3 day coculture (Fig. 4C).
Multiplex cytokine analysis was performed in order to
quantitatively evaluate a paracrine signalling in tumor/
AT-MSC cocultures. A wide plethora of cytokines and
chemokines was detected to be secreted from both cell
types. Combined coculture of these cells exhibited addi-
tive or slightly synergistic effects for most of them, never-
theless significantly increased secretion of G-CSF was
detected, apparently as a response of melanoma cells, and
increased VEGF production proportional to the AT-MSC
number in cocultures (Fig. 5A, B). Taken together mutual
crosstalk between melanoma and AT-MSC within the
tumor microenvironment results in formation of proin-
flammatory and proangiogenic cellular milieu resulting in
Figure 1 AT-MSC coinjection with high melanoma cell dose changes the time of xenograft onset and growth. A.-B. 20% AT-MSC co-adminis-
tered s.c. with 1 × 106 M4Beu significantly shortened time to 100% tumor onset from day 19 (control) to day 12, but did not significantly increase tumor 
burden. C.-D. 10% or 20% AT-MSC admixed with 1.5 × 106 A375 melanoma cells also shortened time of xenograft onset and increased tumor burden 
in nude mice.Kucerova et al. Molecular Cancer 2010, 9:129
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Figure 2 AT-MSC abrogated tumor dormancy of low melanoma cell dose and supported tumor growth. 1 × 105 or 1 × 104 A375 cells resus-
pended in serum-free culture media were injected s.c. either alone or admixed to AT-MSC in ratios 10:1, 1:1 or 1:10. Low A375 cell dose (1 × 105 s.c.) 
resuspended in cell-and-serum free AT-MSC-conditioned media was injected in a separate groups of animals. A. AT-MSC admixed to the A375 at a 
ratio 1:1 or 10:1 significantly increased tumor incidence in nude mice. AT-MSC conditioned media also abrogated tumor dormancy of low A375 mel-
anoma dose. B. Tumor burden in 10:1 and 1:1 AT-MSC coinjected groups was significantly higher in comparison to A375 cell-induced xenografts by 
day 40. C. AT-MSC co-administration resulted in melanoma xenograft tumor growth support proportional to the AT-MSC cell dose (*P < 0.05).Kucerova et al. Molecular Cancer 2010, 9:129
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melanoma growth promotion in vivo. Next, in order to
confirm relevance of the VEGF increased secretion in
vivo we injected group of animals with mixtures of A375/
AT-MSC (2:1 ratio) and treated them with neutralizing
antibody against human VEGF (antiVEGF, Avastin). This
treatment decreased tumor incidence in comparison to
antiVEGF untreated A375/AT-MSC group to some
extent and also resulted in lower average tumor burden
confirming the role of VEGF in the A T -MSC mediated
tumor growth support (Fig. 5C).
Figure 3 AT-MSC increased A375 proliferation and decreased apoptosis in response to cellular stress in direct cocultures in vitro. A. Prolif-
eration of EGFP-A375 cells when mixed with increasing numbers of AT-MSC or maintained in AT-MSC conditioned low-serum medium was evaluated 
by relative fluorescence after 3 days. AT-MSC significantly supported tumor cell proliferation in a dose dependent manner. This effect was significantly 
higher in comparison to proliferation support mediated by conditioned media from the same number of AT-MSC (*p < 0.05). B. A375 cells alone or 
mixed with 10% AT-MSC were maintained in 0%, 0.1% or 0.5% serum-containing medium for 48 hrs and relative Caspase-3/7 activation was evaluated 
by luminescence caspase assay. Caspase-3/7 activity of A375 cells in 0.5% serum-containing medium was set as 100%. AT-MSC significantly decreased 
caspase-3/7 activation in A375 melanoma cells. C. A375 cells alone or mixed with 10% AT-MSC were treated with doxorubicin (DOX), cisplatin (cisPt) 
and 5-fluorouracil (5FU) for 16 hrs under serum-deprivation conditions and Caspase 3/7 activation was evaluated by luminescence caspase assay. Re-
sults were expressed as mean increase in relative luminescence units (RLU) over background luminescence in DMEM cultured cells. AT-MSC could 
significantly decrease extent of caspase activation induced by doxorubicin and cisplatin in A375 cells. D. A375 cells alone or mixed with CFDA-SE-AT-
MSC were treated with doxorubicin, cisplatin and 5-fluorouracil for 20 hrs. Proportion of apoptotic and necrotic A375 cells was determined by Annexin 
V and 7-AAD, respectively. AT-MSC decreased proportion of apoptotic and necrotic A375 cells thus reducing the cytotoxicity effect mediated by dox-
orubicin and cisplatin (*P < 0.05).Kucerova et al. Molecular Cancer 2010, 9:129
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Figure 4 Paracrine signalling in indirect AT-MSC/A375 co-cultures. A. AT-MSC increased colony-formation by A375 cells. A375 cells were plated 
in the lower well part and combined with insert containing AT-MSC, fibroblast or no cells in upper part for 9 days in indirect coculture in vitro. Average 
number of A375 colonies/bottom well is shown in one representative experiment performed in triplicates (*P < 0.05). B. Quantitative RT-PCR was per-
formed on templates isolated from indirectly cocultured A375 and AT-MSC cells. Gene expression level was compared to parental cells and expressed 
as relative gene expression. HGF and cMet expression is sustained upon coculture, CCL5 increases in AT-MSC cells cocultured with A375 cells for 3 
days. C. Semi-quantitative expression analysis of parental A375, AT-MSC and cocultured A375 and AT-MSC cells confirms sustained expression of EGFR, 
VEGF A, VEGF B, VEGFR1, PDGF-bb, SDF-1α, SCF, CCL5, HGF, cMet in AT-MSC; and EGFR, VEGF-A,-B, VEGFR-1,-2 PDGF-bb, SDF-1α, CCL5, HGF, cMet in 
A375.Kucerova et al. Molecular Cancer 2010, 9:129
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Figure 5 Direct AT-MSC/A375 interactions synergistically increase VEGF production and its neutralization can partially inhibit AT-MSC me-
diated tumor onset and growth support. A375, AT-MSC, or A375/AT-MSC were directly co-cultured in complete media for 3 days. A375/AT-MSC 
ratio was A) 2:1 or B) 5:1. The level of cytokines in cell-free supernatants was determined by Bio-Plex cytokine arrays and normalized to the levels ob-
served in the media of A375 cell cultured alone. Mostly, the effects were additive or slightly synergistic. The levels of G-CSF and VEGF were significantly 
increased in both cases and exhibited potent synergistic effect. Data were expressed as average fold induction. ND, not detected. C) 2 × 105 A375 cells 
resuspended in serum-free culture media were injected s.c. either alone or admixed to AT-MSC in ratio 2:1. One group of animals was treated with 1 
mg/kg Avastin twice a week as indicated (antiVEGF group). Left panel: AT-MSC admixed to the A375 at a ratio 2:1 significantly increase tumor growth 
in nude mice and abrogate tumor dormancy (p = 0.0013). VEGF neutralization significantly inhibited protumorigenic AT-MSC mediated effect (p = 
0.0498). Right panel: AntiVEGF treatment significantly decreased tumor burden and counteracted protumorigenic effects of AT-MSC (*p < 0.05).Kucerova et al. Molecular Cancer 2010, 9:129
http://www.molecular-cancer.com/content/9/1/129
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Systemic administration of AT-MSC abrogates tumor 
dormancy and supports tumor growth via SDF-1α/CXCR4 
axis
In order to evaluate whether AT-MSC-mediated tumor
supporting effect is dependent on direct co-implantation
and paracrine stimulation only, we decided to use differ-
ent delivery route for AT-MSC - systemic intravenous
administration frequently used in a clinical setting. AT-
MSC intravenous administration concomitant with the
implantation of low A375 melanoma dose s.c. (2 × 105)
lead to tumor growth in 7 out of 8 animals in contrast to
no tumors growing without AT-MSC treatment (0/4, p =
0.00552, data not shown). Even half of the melanoma cell
dose was sufficient to mediate tumor growth in 67% of
AT-MSC i.v. treated animals in contrast to 12.5% A375
alone s.c. inoculations (Fig. 6A). Consistently with previ-
ously published findings [17], we were not able to detect
substantial proportion of EGFP expressing AT-MSC in
subcutaneous A375 xenografts post-systemic administra-
tion at experiment endpoint by flow-cytometric analysis
of single-cell suspension (data not shown). This might be
caused by transient and/or early AT-MSC homing at the
tumor site, detection limit of the system due to the out-
numbering by rapidly proliferating tumor cells and/or
limited AT-MSC proliferation within the tumor xeno-
transplant. However, we searched for the potential key
mediator(s) that could have affected early homing/incor-
poration of AT-MSC into xenotrasplant implantation site.
Role of SDF-1α/CXCR4 axis in this process was recog-
nized [9-11]. We have confirmed sustained SDF-1α pro-
duction from AT-MSC (1,756.5 pg ± 108.2 pg per 50,000
AT-MSC). Moreover, 28.5% of A375 cells isolated from
A375 xenograft expressed CXCR4 on cell surface (Fig.
6B). We hypothesized that even though the substantial
a m o u n t  o f  A T - M S C  c o u l d  n o t  b e  d e t e c t e d  i n  t u m o r s ,
they actually might have homed very early into the site of
tumor growth and SDF-1α/CXCR4 axis could have been
responsible for the homing. SDF-1α signaling can be
blocked by a CXCR4 antagonist AMD3100 - small mole-
cule inhibitor, which enables to unravel role of this axis in
the protumorigenic effects observed in vivo. In an
attempt to abrogate tumor supportive effect of systemic
AT-MSC administration on A375 xenograft, animals
injected with A375s.c./AT-MSC i.v. were treated with
1.25 mg/kg AMD3100 every other day. Average tumor
volume was decreased in AMD3100 treated group in
comparison to control, but tumor incidences remained
unaffected (Fig. 6C). These data indicated that SDF-1α/
CXCR4 axis contributed to AT-MSC mediated tumor
growth support; however additional mechanism(s) might
be responsible for tumor dormancy abrogation upon sys-
temic injection of AT-MSC.
Figure 6 Systemic AT-MSC administration abrogates A375 tumor 
dormancy and AT-MSC tumor growth support can be partially 
blocked by inhibiting SDF-1α/CXCR4 signalling. A. Systemic ad-
ministration of AT-MSC (106 i.v.) concomitant with the implantation of 
1 × 105 A375 s.c. resulted in abrogation of tumor dormancy in 8 out of 
12 cases in contrast to 1 out of 8 implantations of A375 s.c. alone. B. 
Cultured A375 cells or single-cell suspensions prepared by positive im-
munomagnetic separation of human CD44+ cells from tumor xeno-
transplants were stained with anti-CXCR4 antibody. Flow cytometric 
analysis has shown the absence of the CXCR4 marker on low density 
cultured A375 cells (left), CXCR4 increase upon cell confluence (mid-
dle) and high level of expression on A375 from tumor xenotransplant 
in vivo (right). CXCR4 (filled area), isotype control (open area). C. 2 × 105 
A375 were implanted s.c either alone or coimplanted with AT-MSC 
(106 i.v.). Although all xenografts in AT-MSC injected group started to 
grow, animals treated with AMD3100 inhibitor of SDF-1α/CXCR4 (1.25 
mg/kg every other day s.c.) exhibited significantly lower tumor volume 
in comparison to untreated group (*p < 0.05).Kucerova et al. Molecular Cancer 2010, 9:129
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AT-MSC did not promote growth of glioblastoma cells 
8MGBA in vitro and in vivo
In order to determine whether AT-MSC have tumor sup-
portive effect on different tumor cell type, we have per-
formed coculture experiments in vitro with glioblastoma
cells 8MGBA. 8MGBA cells stably expressing EGFP were
mixed with increasing amounts of AT-MSC or condi-
tioned medium produced from corresponding amount of
AT-MSC cells. Output fluorescence was proportional to
the number of EGFP-8MGBA cells and was not influ-
enced by the amount of admixed AT-MSC cells. Soluble
factors did not support EGFP-8MGBA proliferation and
directly cocultured EGFP-8MGBA/AT-MSC cocultures
exhibited proliferation inhibition at highest 8MGBA/AT-
MSC proportions (Fig. 7A). Neither local coinjection nor
systemic AT-MSC administration promoted glioblastoma
xenograft growth in vivo. Implantation of high glioblas-
toma cell dose s.c. (107 8MGBA) concomitantly with sys-
temic AT-MSC administration resulted in 37.5% tumor
incidence by day 55 (3 out of 8), which represented signif-
icant tumor growth suppression (p = 0.0304). AT-MSC
showed tendency to decrease tumor incidence upon
admixing to low 8MGBA glioblastoma cells dose (Fig.
7B), even though expression analysis has shown similar
expression pattern for the 8MGBA except for constitutive
CXCR4 expression in comparison to melanoma cells
A375 (Fig. 7C). Quantitative analysis has unravelled lower
cMet receptor expression and significantly higher SDF-
1α mRNA level in 8MGBA (Fig. 7C). Multiplex cytokine
analysis was performed in order to quantitatively evaluate
a paracrine signalling in tumor/AT-MSC cocultures.
Combined coculture of 8MGBA/AT-MSC (2:1) exhibited
increased secretion of IL-6, IFN-γ, G-CSF and additive
effects for most of them. Overall outcome demonstrated
several fold higher cytokine levels in 8MGBA/AT-MSC
cocultures which might have been responsible for the
observed inhibitory effect due to the synergistic action of
these soluble factors (Fig. 7D).
Taken together, we have demonstrated both protumori-
genic and antitumorigenic effect AT-MSC on malignant
cell behaviour dependent on the mutual interplay
between malignant and stromal cells to each other.
Discussion
MSC introduction into clinical studies has brought a lot
of excitement about their beneficial effect in severe
pathologic situations. Anyhow, patients treated with
experimental therapies have to be aware of potential
unknown effects. All determinants of MSC-mediated
influence on tumor behaviour have not been fully charac-
terized so far. Discrepancies amongst several studies
reflect the complexity of tumor parenchyma/non-malig-
nant stromal cells' interplay. Adherent multipotent pro-
genitor cells produce plethora of cytokines (Fig. 5) [27-
29], that may modify tumor cell proliferation, metastasis,
self-renewal, responses to cytotoxic stimuli, migration,
and/or adhesion. Prosurvival action of MSC might be
critical in the context of cellular stress as demonstrated in
experiments performed under nutrients/cell limiting
conditions in vitro (Fig. 3). Overall the outcome is clearly
dependent on responsiveness of particular tumor cells in
question and MSC-mediated changes upon interaction.
Moreover, MSC physiological function implies their abil-
i t y  t o  f u n c t i o n  a s  n i c h e  m a r k e r  c e l l s  p o s s i b l y  c r e a t i n g
microregenerative niche for tumor cells that may facili-
tate to overcome hostile conditions in vivo [30,31].
Mutual tumor/MSC interplay leads to functional MSC
changes even under tumor-cell produced soluble factors
[14,32]. MSC do not seem to affect relative tumor growth
rates in vivo, but substantially change tumor incidences
for limiting numbers of inoculated cells [17]. Even soluble
factors produced by A T -MSC were sufficient to enable
the tumor (initiating) cells to overcome nutrition depriva-
tion and engraft within the hostile microenvironment in
vivo  (Fig. 2A). Similar tumor promoting effects were
reported for coinjection of fibroblasts or fibroblast condi-
tioned medium with tumor epithelial cells supporting a
role for soluble factors such as IL-6 [33-35]. These obser-
vations favour the hypothesis of MSC creating protective
regenerative microenvironment by paracrine effects and/
or direct interaction.
Our observations that systemic AT-MSC administra-
tion could increase melanoma xenograft incidence in
immunocompromised host might be also relevant for the
future clinical trials. Dormant tumors frequently present
in patients do not progress into growing tumors unless
angiogenic switch occurs [36]. Whether the systemic
MSC administration might present such stimulus in ther-
apeutic approaches remains to be further carefully
observed. MSC incorporation into tumors can be altered
by anti-inflammatory treatment thereby abrogating
inhibitory effect of MSC on pancreatic tumor growth
[37]. Hung et al. have shown MSC incorporation into
established subcutaneous HT-29 xenotransplants accom-
panied by loss of mesenchymal concomitant with
endothelial marker expression [38]. Tumor-driven differ-
entiation of MSC into phenotype of activated fibroblasts
was described as another mechanism relevant for the
MSC-mediated tumor progression [14,32]. However,
Djouad et al. could not confirm MSC incorporation into
the tumor on syngeneic model and they have supported
the idea of systemic immunosuppression as a mechanism
facilitating increased tumor incidence in syngeneic situa-
tion in vivo [17].
D i r e c t  c o c u l t u r e  o f  A T - M S C  w i t h  g l i o b l a s t o m a  c e l l s
has shown the absence of proliferation support in vitro
being in line with decreased tumor incidences in
8MGBA/AT-MSC inoculations (Fig. 7). Both tumor cellKucerova et al. Molecular Cancer 2010, 9:129
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Figure 7 8MGBA glioblastoma proliferation and tumor incidence was not increased by AT-MSC. A. Proliferation of EGFP-8MGBA cells when ad-
mixed with increasing numbers of AT-MSC or maintained in AT-MSC conditioned low-serum medium was evaluated by relative fluorescence after 3 
days. AT-MSC did not support tumor cell proliferation in comparison to control without AT-MSC. EGFP-8MGBA proliferation was significantly inhibited 
in co-culture containing 39% of AT-MSC (*p < 0.05). B. 8MGBA cells 1.5 × 106 or 1 × 107 were injected s.c. either alone, admixed to AT-MSC at a ratio 
1:1 or 1:10 or 1 × 106 AT-MSC i.v. AT-MSC decreased the tumor incidence by day 55 from 60% in 8MGBA alone group to 33% in 8MGBA/AT-MSC 10:1 
group and 17% in 8MGBA/AT-MSC 1:1 group. Systemic AT-MSC administration significantly decreased tumor incidence to 37.5% (*p = 0.0304). C. 
8MGBA expression profile demonstrated expression of EGFR, VEGF-A,-B, VEGFR-1,-2 PDGF-bb, cKit, SDF-1α (high), CXCR4, CCL5, HGF, cMet (low). Quan-
titative differences were detected in higher level of SDF-1α expression and lower level of cMet receptor expression in comparison to A375 melanoma. 
D. 8MGBA, AT-MSC, or 8MGBA/AT-MSC (ratio 2:1) were directly co-cultured in complete media for 3 days. Level of cytokines in cell-free supernatants 
was determined by Bio-Plex cytokine arrays and normalized to the levels observed in the media of 8MGBA cells cultured alone. Mostly, the effects were 
additive, increased level of IL-1β and IFN-γ was observed in directly cocultured cells. Data were expressed as average fold induction. ND, not detected.Kucerova et al. Molecular Cancer 2010, 9:129
http://www.molecular-cancer.com/content/9/1/129
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types express HGF, VEGF-A and PDGF-bb - growth fac-
tors implicated in the tumor-directed MSC migration
(Fig. 4C and 7C) [27,39-41]. Moreover, expression of
endothelial markers such as VEGFR1 and VEGFR2 on
AT-MSC suggests the AT-MSC potential to contribute to
tumor vasculature and/or premetastatic niche formation
[30,42]. High level of G-CSF, renowned for the promotion
of survival of leukocytes and their recruitment to the tis-
sues, was detected in tumor/AT-MSC cocultures and
contributed to formation of proinflammatory microenvi-
ronment [43]. Most prominent synergistic increase of
VEGF in A375/AT-MSC cocultures indicated its poten-
tial role in tumor promotion. We suggest that high local
VEGF concentrations contributed to the protumorigenic
action of AT-MSC, although its neutralization could not
completely abrogate AT-MSC effects indicative of role of
other cytokines as well (Fig. 5C). According to the previ-
ously published data, CCL5 increase could contribute to
higher metastatic potential of tumor cells rather than the
proliferation increase [15]. Our experimental data con-
firm that both local and systemic AT-MSC administra-
tion exerted protumorigenic action on A375. Intravenous
A T -MSC delivery resulted in abrogation of tumor dor -
mancy (Fig. 6A). It has been previously proposed that
SDF-1α/CXCR4 signalling played role in AT-MSC hom-
ing within the sites of tumor formation and recently pub-
lished data have demonstrated that inhibition of this axis
by small molecule inhibitor AMD3100 could abrogate
their migration towards prostate cancer cells [44]. More
importantly, AMD3100 administration could abrogate
glioblastoma regrowth by preventing post-irradiation
recruitment of bone marrow progenitor cells [45]. Our
data also demonstrate the contribution of SDF-1α/
CXCR4 signalling to AT-MSC-mediated A375 tumor
growth. TGFβ is another key molecule playing a role in
cell recruitment and affecting expression of other
chemokines thereby also modulating tumor microenvi-
ronment [46]. TGFβ signalling might be another mecha-
nism involved in tumor dormancy abrogation as SDF-1α/
CXCR4 inhibition was insufficient to counteract AT-
MSC mediated effect.
It seems as though AT-MSC produced tumor-inhibi-
tory environment for given human glioblastoma cell line
8MGBA in our study similar to reported situations of
cancer inhibiting inflammatory reaction [43]. We demon-
strated that these glioblastoma cells were put into rela-
tively cytokine "rich" environment produced by AT-MSC
containing IL-1β, IL-1ra, IL-2, IL-4, IL-6, IL-8, TNF-α,
IFN-γ, CCL5, CCL26, CXCL10, PDGF-bb. These could
act in paracrine fashion alone or in combination to sup-
press glioblastoma cell growth such as described for syn-
ergistic inhibitory effect of TNF-α and IP-10 (CXCL10)
[47]. Indeed, Nakamura et al. reported direct antiglioma
role of unmanipulated MSC resulting in prolonged ani-
mal survival upon intracranial implantation [23].
Although tumor cells were put under the influence of
similar AT-MSC produced proinflammatory and proan-
giogenic factors, we have observed contrastingly different
responses. AT-MSC presented either tumor supportive
or inhibitory effects depending on the inherent tumor cell
properties and response to these factors.
Conclusions
Our study provided data to document both tumor-pro-
moting and tumor-suppressive effects of AT-MSC on two
different human tumor cell lines both in vitro and in vivo.
Taken together, the complexity of tumor growth process
and AT-MSC-mediated influence on tumor growth is
reflected in this study. It highlights the necessity to study
the tumor development in the context of tumor microen-
vironment to unravel determinants of tumor growth with
the direct impact on therapeutic intervention [48]. More-
over, all these studies are inevitable to sufficiently
describe potential MSC-attributable effects on the tumor
behaviour in the light of wider MSC clinical use in both
non-malignant and malignant therapeutic context.
Methods
Cells and Chemicals
Human melanoma cell lines A375 (ECACC No.
88113005), M4Beu, human fibroblasts (kindly provided
by Dr. J. Bizik, CRI SAS, Bratislava), and glioblastoma
multiforme 8MGBA (kindly provided by Dr. Perzelova,
Med. School, Comenius University, Bratislava) were cul-
tured in Dulbecco's modified Eagle medium (DMEM)
supplemented with 5% fetal calf serum (FCS) and Antibi-
otic-Antimycotic mix (GIBCO BRL, Gaithesburg, MD).
EGFP-A375 and EGFP-8MGBA cells lines stably express-
ing enhanced green fluorescent protein were prepared as
described elsewhere [49] and cultured as above. Cells
were kept in humidified atmosphere and 5% CO2 at 37°C.
AT-MSC were derived by plastic adherence technique as
previously described in [24]. Briefly, AT-MSC cells were
expanded from adherent cells obtained from stromal-
vesicular fraction upon collagenase type VIII digestion of
lipoaspirate obtained from healthy persons, who pro-
vided an informed consent. Cells were expanded in low
glucose (1,000 mg/ml) DMEM supplemented with 10%
Mesenchymal stem cell stimulatory supplement (human,
MSCSS) (StemCell Technologies, Grenoble, France) and
Antibiotic-antimycotic (GIBCO BRL, Gaithesburg, MD).
AT-MSC were characterized by surface marker expres-
sion as CD44+, CD73+, CD90+, CD105+, CD14-, CD34-,
CD45- population and AT-MSC were capable of differen-
tiation into adipocytes and osteoblasts. Conclusions were
drawn from similar results of experiments performed
with two different isolates if not specified otherwise.Kucerova et al. Molecular Cancer 2010, 9:129
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Cell-free AT-MSC conditioned medium was collected
from 80% confluent AT-MSC cultures maintained in
serum-free DMEM for 24 hrs and used for inoculations
in vivo.
All chemicals were purchased from Sigma (St. Louis,
MO) if not stated otherwise.
Tumor cell and AT-MSC cocultures
For proliferation evaluation, triplicates of 4,000 EGFP-
A375 or EGFP-8MGBA tumor cells/well were seeded in
black-walled 96-well plates (Greiner Bio-One Intl. AG)
with or without increasing numbers of AT-MSC for over-
night. Same amounts of AT-MSC in triplicates were
seeded in parallel 96-well plates in 1% and 2.5% FBS con-
taining DMEM for preparation of AT-MSC conditioned
media. This media after overnight incubation was trans-
ferred into corresponding wells to evaluate tumor cell
proliferation in AT-MSC conditioned medium. Medium
was replaced every day and relative proliferation was
evaluated by PolarStar OPTIMA reader (BMG Labtech-
nologies, Offenburg, Germany) on day 3. Values were
expressed as means of relative fluorescence ± SD, where
EGFP tumor cell fluorescence in appropriate medium
DMEM without AT-MSC was set to 100% by default. It
was previously determined, that there was linear correla-
tion between fluorescence intensity and number of EGFP
expressing cells under these experimental culture condi-
tions.
For apoptosis evaluation, quadruplicates of 15,000
tumor cells/well were seeded either alone or into wells
containing 1,500 AT-MSC/well in 96-well plates for over-
night. Cells were washed and treated with 0%, 0.1% and
0.5% serum containing media for 3 days to determine the
extent of serum-deprivation induced apoptosis. Cells
were treated with 1 μg/ml doxorubicin, 5 μg/ml cisplatin
or 50 μg/ml 5-fluorouracil in serum-free or 5% serum
containing media for 16 hrs to evaluate extent of cytotox-
icity. Caspase-3/7 activation was determined by Caspase-
Glo® 3/7 Assay (Promega, Madison, WI) on LUMIstar
G A L A X Y  r e a d e r  ( B M G  L a b t e c h n o l o g i e s ,  O f f e n b u r g ,
Germany). Values were expressed as fold increase in rela-
tive luminescence units (RLU) in comparison to tumor
cells maintained in media alone.
For flow cytometric determination of apoptotic and
necrotic cell proportions in direct cocultures, adherent
A T - M S C  w e r e  l a b e l l e d  w i t h  5  μ M  c a r b o x y - fl u o r e s c e i n
diacetate, succinimidyl ester (CFDA-SE, Molecular
Probes, Eugene, OR) in a serum-free DMEM for 15 min
at 37°C. Medium was replaced for standard culture
medium for overnight incubation. 100,000 tumor cells/
well were seeded with or without 10,000 CFDA-SE-AT-
MSC/well in duplicates in 24-well plates and serum-
deprived for overnight. Cells were treated with 200 ng/ml
doxorubicin, 5 μg/ml cisplatin or 50 μg/ml 5-fluorouracil
in 5% serum containing media for 20 hrs. Apoptotic cells
were stained with Phycoerythrin-labelled Annexin V
(Invitrogen, Carlsbad, CA); dead cells were detected with
7-AAD viability dye. Stained cells were analyzed using an
EPICS ALTRA flow cytometer (Beckman Coulter, Fuller-
ton, CA) equipped with Expo 32 program.
Colony-formation ability was evaluated in indirect
tumor cell coculture with AT-MSC or fibroblasts. Tumor
cells (280/cm2 in 6-well plates) were plated into wells and
combined with AT-MSC or fibroblasts physically sepa-
rated in upper compartment and seeded on 0.4 μm cell
culture inserts (5 × 104 cell/insert) (Nalge Nunc Interna-
tional, Rochester, NY). Cells were maintained for 9 days
in standard culture media. Average total number of A375
colonies per well was counted after Giemsa-Romanowski
staining. Conclusions were drawn from three indepen-
dent experiments.
Analysis of gene expression
Tumor cells were cultured with or without AT-MSC
seeded on 0.4 μm inserts (105 cells/insert) (Nalge Nunc
International, Rochester, NY) for 3 days. Total RNA was
isolated from 0.5 × 106 8MGBA, A375, AT-MSC, A375
co-cultured cells and AT-MSC co-cultured cells collected
from inserts by RNeasy mini kit (Qiagen, Hilden, Ger-
many) and treated with RNase-free DNase (Qiagen,
Hilden, Germany). RNA was reverse transcribed with
RevertAid™ H minus First Strand cDNA Synthesis Kit
(Fermentas, Hanover, MD). 200 ng of cDNA was subject
to standard PCR performed in 1× PCR Master Mix (Fer-
mentas, Hanover, MD) with 35 cycles and gel resolved on
2% agarose or 4% MetaPhor® Agarose (Lonza, Rockland,
ME, USA) for qualitative analysis.
Quantitative PCR was performed in 1× ABsolute™
QPCR SYBR® Green Mix (ABgene, Surrey, UK), 0.16 μM
primers and 500 ng of template cDNA on RotorGene
2000 (Corbett Research, Sydney, Australia) and analyzed
by RotorGene Software version 4.6. Primer sequences
were used as previously published [15,27]. Relative gene
expression change was calculated according to the for-
mula Fold increase = (reaction efficiency*2)ΔΔCt, where
ΔΔCt = [{CtGOI(control cells)-CtGAPDH(control cells)}-{CtGOI(treated
cells)-CtGAPDH(treated cells)}]. GAPDH expression was taken
as endogenous reference gene (GOI = gene of interest).
Analysis was performed twice in triplicates and data
expressed as means ± SE.
CXCR4 expression
CXCR4 surface expression was analyzed in A375 cul-
tures, or A375 cells isolated from tumor xenografts.
Tumors were treated with 0.15% collagenase VIII, and
0.05 mg/ml DNAse I for 45 min at 37°C. Cells were sieved
through 30 μm pre-separation filters (Miltenyi Biotec,
Bergisch Gladbach, Germany) to obtain single-cell sus-Kucerova et al. Molecular Cancer 2010, 9:129
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pension and immunomagnetically separated by EasySep
human FITC selection kit (StemCell Technologies, Van-
couver, BC, Canada) by positive selection with FITC con-
jugated human specific anti-CD44 antibody (Millipore,
Billerica, USA). CD44 positive cells were stained with PE-
conjugated anti CXCR4 antibody (Invitrogen, Carlsbad,
CA), anti-IgG2a isotype control (Invitrogen, Carlsbad,
CA) and by flow cytometer. Representative result out of
three independent experiments is shown.
Cytokine secretion analysis
50,000 A375 or 8MGBA, 25,000 AT-MSC cells alone
plated in wells, 10,000 AT-MSC cells alone, 50,000 A375
(or 8MGBA) cells mixed with AT-MSC (ratio 5:1 or 2:1)
were cultured in complete culture medium for three days.
Cell-free supernatants were collected and subjected to
human Bio-Plex™ 27-plex Cytokine Assay (Bio-Rad Labo-
ratories Inc, Hercules, CA). Measurements were per-
formed on Luminex 100 System (Luminex Corporation,
Austin, TX) in duplicates with two different AT-MSC iso-
lates. Results were expressed as means and relative
cytokine expression was calculated by comparison to
cytokine production from A375 (8MGBA) cells respec-
tively.
SDF-1α level was determined in cell free supernatants
prepared as above by human SDF1-α Quantikine Immu-
noassay (R&D Systems Inc.) on PolarStar OPTIMA
reader (BMG Labtechnologies, Offenburg, Germany) as
recommended by manufacturer.
Experiments in vivo
Six weeks old athymic nude mice (Balb/c-nu/nu) were
used in accordance with institutional guidelines under
the approved protocols. It was determined in preliminary
studies that 106 M4Beu cells, 1.5 × 106 A375 cells or 107
8MGBA cells injected s.c. exhibit 100% tumor incidence.
Following cell suspensions were injected in high dose
coinjection studies: 1.5 × 106 A375 cells, 1.5 × 106 A375 +
1.5 × 105 AT-MSC (10%AT-MSC), 1.5 × 106 A375 + 3 ×
105 AT-MSC (20% AT-MSC), 1 × 106 M4Beu cells, 1 × 106
M4Beu + 1 × 105 AT-MSC (10% AT-MSC) (in 100 μl of
PBS s.c. into the flank). In an independent study animals
received low tumor cell dose (tumor incidence 1/10) of 1
× 104, 1 × 105 or 2 × 105 A375 cells s.c as indicated.
Groups of animals were directly coinjected with 1 × 106, 1
× 105, 1 × 104 AT-MSC in admixture s.c., or s.c adminis-
tered 1 × 105 tumor cells were resuspended in AT-MSC
conditioned media prior to injection. Independent group
of animals was systemically administered with 1 × 106
AT-MSC i.v. into the lateral tail vein concomitantly with
s.c. administration of A375 cells alone. Animals were sub-
sequently treated with 1.25 mg/kg AMD3100 every other
day s.c. or 1 mg/kg Avastin (Bevacizumab, Roche, kindly
provided by National Cancer Institute, Bratislava) i.p.
twice a week where indicated.
For glioblastoma xenograft study animals received low
(1.5 × 106) 8MGBA cell dose cells s.c. Experimental
groups of animals were directly coinjected with 1 × 106 or
1 × 105 AT-MSC in admixture s.c. Independent group of
animals was systemically administered with 1 × 106 AT-
MSC i.v. into the lateral tail vein concomitantly with s.c.
administration of 8MGBA high cell dose (107).
Animals were regularly inspected for tumor incidence
and designated tumor-free when no palpable rigid struc-
tures exceeding 1 mm in diameter could have been
detected. Growing tumors were measured by calliper and
volume was calculated according to formula volume =
length × width2/2. Animals were sacrificed at the point,
when the tumors exceeded 1 cm in diameter. Results were
evaluated as mean volume ± SE.
Statistical analysis
Student's t test was used for comparison between the
groups, differences in tumor incidences were evaluated
by log-rank test, P value < 0.05 was considered signifi-
cant.
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